Hossein Fallah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hossein Fallah has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Beydolah Shahouzehi
Cardiovascular Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran
5 shared publications - Durdi Qujeq
Department of Biochemistry, School of Medicine, Babol University of Medical Sciences, Babol, Iran
3 shared publications - Yaser Masoumi-Ardakani
Physiology Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran
3 shared publications - Ali Nosrati Andevari
Department of Clinical Biochemistry, Afzalipour Faculty of Medicine Kerman University of Medical Sciences Kerman Iran
2 shared publications - Asghar Heidari Firoozjaee
Department of Biochemistry, School of Medicine, Babol University of Medical Sciences, Babol, Iran
2 shared publications Athena Rajaie
Department of Clinical Biochemistry, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
2 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Wolters Kluwer Health in International Journal of Surgery Protocols
Protocol for a systematic review and meta-analysis: the effects of atorvastatin on interleukin-1β (IL-1β) levels in patients
Background: Atorvastatin is a lipophilic 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor with potential pleiotropic anti-inflammatory effects. Interleukin-1β (IL-1β) is a pro-inflammatory cytokine implicated in cardiovascular, metabolic, and autoimmune diseases. However, evidence regarding the effect of atorvastatin on IL-1β concentrations is inconsistent. Objective: To systematically evaluate the effect of atorvastatin on IL-1β concentrations in human participants. Methods: This protocol follows PRISMA-P guidelines. We will search PubMed, Scopus, Web of Science, and Embase for English-language, peer-reviewed studies published from January 2005 through October 2025. Eligible studies will include randomized controlled trials, controlled non-randomized studies, and uncontrolled longitudinal before-after studies of atorvastatin monotherapy that report IL-1β at baseline and follow-up, change scores, or comparable endline values in the intervention and comparator groups. We will synthesize results separately by study design and comparator structure. If appropriate after assessing clinical and methodological comparability, we will conduct cross-design synthesis only as an exploratory analysis. Mean differences (MD) or standardized mean differences (SMD) will be pooled using random-effects models. We will assess heterogeneity using I 2 and evaluate the certainty of the evidence using GRADE. Outcomes: We will estimate whether atorvastatin changes IL-1β concentrations and explore whether the dose, treatment duration, clinical condition, study design, and assay method modify the estimated effect. Ethics and dissemination: Ethical approval is not required because we will use only publiclyavailable data. We will submit findings to a peer-reviewed journaland present them at scientific meetings.
- 10 November 2026
- Published by Wolters Kluwer Health in International Journal of Surgery Protocols
Open AccessProtocol for a systematic review and meta-analysis: the effects of atorvastatin on interleukin-1β (IL-1β) levels in patients
Background: Atorvastatin is a lipophilic 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor with potential pleiotropic anti-inflammatory effects. Interleukin-1β (IL-1β) is a pro-inflammatory cytokine implicated in cardiovascular, metabolic, and autoimmune diseases. However, evidence regarding the effect of atorvastatin on IL-1β concentrations is inconsistent. Objective: To systematically evaluate the effect of atorvastatin on IL-1β concentrations in human participants. Methods: This protocol follows PRISMA-P guidelines. We will search PubMed, Scopus, Web of Science, and Embase for English-language, peer-reviewed studies published from January 2005 through October 2025. Eligible studies will include randomized controlled trials, controlled non-randomized studies, and uncontrolled longitudinal before-after studies of atorvastatin monotherapy that report IL-1β at baseline and follow-up, change scores, or comparable endline values in the intervention and comparator groups. We will synthesize results separately by study design and comparator structure. If appropriate after assessing clinical and methodological comparability, we will conduct cross-design synthesis only as an exploratory analysis. Mean differences (MD) or standardized mean differences (SMD) will be pooled using random-effects models. We will assess heterogeneity using I 2 and evaluate the certainty of the evidence using GRADE. Outcomes: We will estimate whether atorvastatin changes IL-1β concentrations and explore whether the dose, treatment duration, clinical condition, study design, and assay method modify the estimated effect. Ethics and dissemination: Ethical approval is not required because we will use only publiclyavailable data. We will submit findings to a peer-reviewed journaland present them at scientific meetings.
- 13 May 2026
- Published by Springer Nature in International Journal of Diabetes in Developing Countries
- Vol. 46 (3) , 889-891
Response to letter to editor—Letter to the Letter: “The effects of atorvastatin consumption on blood levels of sortilin, glycemic, and lipid indices in type 2 diabetic patients: A randomized clinical trial”
- 13 May 2026
- Published by Springer Nature in International Journal of Diabetes in Developing Countries
- Vol. 46 (3) , 889-891
Response to letter to editor—Letter to the Letter: “The effects of atorvastatin consumption on blood levels of sortilin, glycemic, and lipid indices in type 2 diabetic patients: A randomized clinical trial”
- 19 December 2025
- Published by Springer Nature in European Journal of Applied Physiology
- Vol. 126 (5) , 2695-2705
Effect of ischemic postconditioning on inflammatory and oxidative markers in methadone-treated rats during myocardial ischemia-reperfusion injury
Purpose Ischemia-reperfusion injury (IRI) poses a major challenge in cardiovascular therapy due to inflammation and oxidative stress. Ischemic postconditioning (IPoC) offers cardioprotection against IRI, but its efficacy may be compromised by chronic methadone use. This study examined the impact of IPoC on inflammatory and oxidative biomarkers in methadone-treated rats subjected to myocardial IRI. Methods Twenty-four male Wistar rats were divided into four groups: IRI, methadone-treated IRI (IRI-M), IPoC-treated IRI (IRI-IPoC), and methadone-treated IPoC-IRI (IRI-M-IPoC). Inflammatory proteins (IL-1β, IL-6, TNF-α), oxidative markers (SOD, GPx, TAS), and MDA levels were measured using commercial kits. Gene expression of inflammatory and antioxidant (NRF2, SOD, and GPx) was measured using Real-time PCR assay. Results IPoC significantly reduced the expression of inflammatory genes (IL-1β, IL-6, TNF-α, NF-κB) and enhanced antioxidant responses (NRF2, SOD, GPx) in rats subjected to myocardial IRI. Methadone-treated rats (IRI-M) exhibited elevated inflammatory markers and suppressed antioxidant gene expression. The combination group (IRI-M-IPoC) showed partial restoration of antioxidant activity and moderate reduction in inflammation, but these effects were significantly weaker than those observed in the IPoC-only group. Conclusion IPoC effectively reduces myocardial IRI by modulating inflammation and oxidative stress. However, chronic methadone use impairs these protective effects, likely through redox imbalance and enhanced inflammatory signaling. These findings confirm the need for optimized therapeutic strategies, potentially including antioxidant support, for patients on opioid maintenance therapy. Further research is warranted to clarify the molecular interplay between opioids and conditioning interventions. Graphical abstract
- 19 December 2025
- Published by Springer Nature in European Journal of Applied Physiology
- Vol. 126 (5) , 2695-2705
Effect of ischemic postconditioning on inflammatory and oxidative markers in methadone-treated rats during myocardial ischemia-reperfusion injury
Purpose Ischemia-reperfusion injury (IRI) poses a major challenge in cardiovascular therapy due to inflammation and oxidative stress. Ischemic postconditioning (IPoC) offers cardioprotection against IRI, but its efficacy may be compromised by chronic methadone use. This study examined the impact of IPoC on inflammatory and oxidative biomarkers in methadone-treated rats subjected to myocardial IRI. Methods Twenty-four male Wistar rats were divided into four groups: IRI, methadone-treated IRI (IRI-M), IPoC-treated IRI (IRI-IPoC), and methadone-treated IPoC-IRI (IRI-M-IPoC). Inflammatory proteins (IL-1β, IL-6, TNF-α), oxidative markers (SOD, GPx, TAS), and MDA levels were measured using commercial kits. Gene expression of inflammatory and antioxidant (NRF2, SOD, and GPx) was measured using Real-time PCR assay. Results IPoC significantly reduced the expression of inflammatory genes (IL-1β, IL-6, TNF-α, NF-κB) and enhanced antioxidant responses (NRF2, SOD, GPx) in rats subjected to myocardial IRI. Methadone-treated rats (IRI-M) exhibited elevated inflammatory markers and suppressed antioxidant gene expression. The combination group (IRI-M-IPoC) showed partial restoration of antioxidant activity and moderate reduction in inflammation, but these effects were significantly weaker than those observed in the IPoC-only group. Conclusion IPoC effectively reduces myocardial IRI by modulating inflammation and oxidative stress. However, chronic methadone use impairs these protective effects, likely through redox imbalance and enhanced inflammatory signaling. These findings confirm the need for optimized therapeutic strategies, potentially including antioxidant support, for patients on opioid maintenance therapy. Further research is warranted to clarify the molecular interplay between opioids and conditioning interventions. Graphical abstract
- Open Access
- 17 May 2025
- Published by Maad Rayan Publishing Company in Journal of Kerman University of Medical Sciences
- Vol. 32 (1) , 1-7
Antioxidant Effects of Pioglitazone and Interleukin-1 receptor-associated kinase inhibitor on Oxidative Stress Indices in obese C57BL/6J Mice
Background: Pioglitazone possesses antioxidant properties, whereas the antioxidant effects of IRAKi (Interleukin-1 receptorassociated kinase inhibitor; an anti-inflammatory agent) remain less established. Therefore, we investigated the antioxidant properties of IRAKi and pioglitazone in the liver of obese C57BL/6J mice. Methods: Thirty-five mice were randomly assigned to five groups (n=7); Control, high-fat diet (HFD), HFD-IRAKi, HFD-pioglitazone (PIO), and HFD-IRAKi-PIO. After 12 weeks on an HFD, IRAKi (2 mg/kg, intraperitoneally, three times a week) and pioglitazone (10 mg/kg, orally, daily) were administered for two weeks. The expression levels of Superoxide dismutase (SOD) and glutathione peroxidase (GPx) genes were evaluated through Real-time PCR analysis. Malondialdehyde (MDA), SOD, total antioxidant status (TAS), GPx, and total oxidant status (TOS) levels were quantified. Results: HFD increased oxidative stress. IRAKi and pioglitazone, administered separately, increased SOD and TAS while reducing MDA and TOS compared to the HFD group. However, neither treatment significantly altered GPx activity. The combination of IRAKi and pioglitazone exhibited superior antioxidant effects compared to their separate administrations. Specifically, the combined treatment improved both GPx and SOD levels as well as their gene expression. Conclusion: Our findings demonstrate the antioxidative effects of IRAKi and pioglitazone in C57BL/6J mice. Notably, their combination produced additive effects, enhancing the antioxidant defense system in the liver. These results suggest that IRAKi and pioglitazone, when used together, may serve as a promising therapeutic approach for managing oxidative stress in liver disease. By providing a dual mechanism of action, this combination highlights its potential for broader clinical applications in chronic disease management.
- 17 May 2025
- Published by Maad Rayan Publishing Company in Journal of Kerman University of Medical Sciences
- Vol. 32 (1) , 1-7
Open AccessAntioxidant Effects of Pioglitazone and Interleukin-1 receptor-associated kinase inhibitor on Oxidative Stress Indices in obese C57BL/6J Mice
Background: Pioglitazone possesses antioxidant properties, whereas the antioxidant effects of IRAKi (Interleukin-1 receptorassociated kinase inhibitor; an anti-inflammatory agent) remain less established. Therefore, we investigated the antioxidant properties of IRAKi and pioglitazone in the liver of obese C57BL/6J mice. Methods: Thirty-five mice were randomly assigned to five groups (n=7); Control, high-fat diet (HFD), HFD-IRAKi, HFD-pioglitazone (PIO), and HFD-IRAKi-PIO. After 12 weeks on an HFD, IRAKi (2 mg/kg, intraperitoneally, three times a week) and pioglitazone (10 mg/kg, orally, daily) were administered for two weeks. The expression levels of Superoxide dismutase (SOD) and glutathione peroxidase (GPx) genes were evaluated through Real-time PCR analysis. Malondialdehyde (MDA), SOD, total antioxidant status (TAS), GPx, and total oxidant status (TOS) levels were quantified. Results: HFD increased oxidative stress. IRAKi and pioglitazone, administered separately, increased SOD and TAS while reducing MDA and TOS compared to the HFD group. However, neither treatment significantly altered GPx activity. The combination of IRAKi and pioglitazone exhibited superior antioxidant effects compared to their separate administrations. Specifically, the combined treatment improved both GPx and SOD levels as well as their gene expression. Conclusion: Our findings demonstrate the antioxidative effects of IRAKi and pioglitazone in C57BL/6J mice. Notably, their combination produced additive effects, enhancing the antioxidant defense system in the liver. These results suggest that IRAKi and pioglitazone, when used together, may serve as a promising therapeutic approach for managing oxidative stress in liver disease. By providing a dual mechanism of action, this combination highlights its potential for broader clinical applications in chronic disease management.
- Open Access
- 30 January 2025
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 25 (1) , 1-11
Exploring serum miR-33b as a novel diagnostic marker for hypercholesterolemia and obesity: insights from a pilot case-control study
Obesity and atherosclerosis are significant metabolic diseases characterized by disrupted lipid metabolism. MicroRNAs (miRNAs) are small, conserved, non-coding RNA sequences consisting of approximately 22 nucleotides, playing crucial roles in biological and pathological functions. Among these, miR-33a/b is particularly associated with metabolic diseases, notably obesity and atherosclerosis. In this pilot case-control study, 45 subjects were examined, and serum miR-33b levels were measured in three groups: a control group, hypercholesterolemic (HC) subjects without obesity (HC group), and obese subjects without hypercholesterolemia (obese group). Serum miR-33b levels were determined using the real-time PCR method. The expression of miR-33b was significantly higher in the HC and obese groups compared to the control group (p < 0.001). The Body mass index (BMI) in the obese group was significantly higher than in the control and HC groups (p < 0.001). Additionally, serum total cholesterol (TC) and high-density lipoprotein cholesterol (HDL-c) levels were higher in the HC group compared to both the control and obese groups. Our study demonstrated a correlation between serum miR-33b levels and HC and obesity. Finally, the ROC analysis demonstrated that miR-33b had an AUC of 0.74 for identifying hypercholesterolemia and an AUC of 0.76 for identifying obesity, indicating its acceptable diagnostic value alongside traditional markers. Therefore, serum miR-33b levels can be considered as a potential biomarker for obesity and hypercholesterolemia, but these finding are preliminary and further investigation is necessary in larger samples to confirm these associations.
- 30 January 2025
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 25 (1) , 1-11
Open AccessExploring serum miR-33b as a novel diagnostic marker for hypercholesterolemia and obesity: insights from a pilot case-control study
Obesity and atherosclerosis are significant metabolic diseases characterized by disrupted lipid metabolism. MicroRNAs (miRNAs) are small, conserved, non-coding RNA sequences consisting of approximately 22 nucleotides, playing crucial roles in biological and pathological functions. Among these, miR-33a/b is particularly associated with metabolic diseases, notably obesity and atherosclerosis. In this pilot case-control study, 45 subjects were examined, and serum miR-33b levels were measured in three groups: a control group, hypercholesterolemic (HC) subjects without obesity (HC group), and obese subjects without hypercholesterolemia (obese group). Serum miR-33b levels were determined using the real-time PCR method. The expression of miR-33b was significantly higher in the HC and obese groups compared to the control group (p < 0.001). The Body mass index (BMI) in the obese group was significantly higher than in the control and HC groups (p < 0.001). Additionally, serum total cholesterol (TC) and high-density lipoprotein cholesterol (HDL-c) levels were higher in the HC group compared to both the control and obese groups. Our study demonstrated a correlation between serum miR-33b levels and HC and obesity. Finally, the ROC analysis demonstrated that miR-33b had an AUC of 0.74 for identifying hypercholesterolemia and an AUC of 0.76 for identifying obesity, indicating its acceptable diagnostic value alongside traditional markers. Therefore, serum miR-33b levels can be considered as a potential biomarker for obesity and hypercholesterolemia, but these finding are preliminary and further investigation is necessary in larger samples to confirm these associations.
- Open Access
- 12 August 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (8) , e0306977
Relationship between types and levels of free fatty acids, peripheral insulin resistance, and oxidative stress in T2DM: A case-control study
Free Fatty Acids (FFAs) are vital for energy homeostasis and the pathogenesis of a variety of diseases, including diabetes. For the first time, we presumed and investigated the types and levels of FFAs and their links to Insulin Resistance (IR) and Oxidative Stress (OS) in T2DM. A case-control study was conducted on 60 individuals with diabetes, 60 prediabetics with IFG, and 60 control groups. A Gas Chromatography Flame Ionization Detector (GC-FID) was used to estimate FFAs, which were then classified based on length and saturation. Indeed, antioxidant parameters such as TAC, MDA levels, PON-1, SOD-3, and CAT activity were assessed. Higher levels of LCFFA, SFFA, USFFA, and total FFA were found in people with diabetes and prediabetes. These levels were also linked to higher levels of HOMA-IR, BMI, FBS, HbA1C, and MDA, but lower levels of antioxidants. Furthermore, adjusting the above FFAs with age, sex, and antihypertensive medication increased T2DM development. SCFFA and ω3/6 fatty acids had a negative relationship with HOMA-IR, FBS, and insulin and a positive relationship with TAC. Adjusted SCFFA reduces T2DM risk. According to our models, total FFA is utilized to diagnose diabetes (AUC = 83.98, cut-off > 919 μM) and SCFFA for prediabetes (AUC = 82.32, cut-off < 39.56 μM). Total FFA (≥ 776 μM), LCFFA (≥ 613 μM), SFFA (≥ 471 μM), and USFFA (≥ 398 μM) all increase the risk of T2DM by increasing OS, BMI, and HOMA-IR. On the other hand, SCFFAs (≥ 38.7 μM) reduce the risk of T2DM by reducing BMI, HOMA-IR, and OS. SCFFAs and total FFAs can be used for the diagnosis of prediabetes and diabetes, respectively.
- 12 August 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (8) , e0306977
Open AccessRelationship between types and levels of free fatty acids, peripheral insulin resistance, and oxidative stress in T2DM: A case-control study
Free Fatty Acids (FFAs) are vital for energy homeostasis and the pathogenesis of a variety of diseases, including diabetes. For the first time, we presumed and investigated the types and levels of FFAs and their links to Insulin Resistance (IR) and Oxidative Stress (OS) in T2DM. A case-control study was conducted on 60 individuals with diabetes, 60 prediabetics with IFG, and 60 control groups. A Gas Chromatography Flame Ionization Detector (GC-FID) was used to estimate FFAs, which were then classified based on length and saturation. Indeed, antioxidant parameters such as TAC, MDA levels, PON-1, SOD-3, and CAT activity were assessed. Higher levels of LCFFA, SFFA, USFFA, and total FFA were found in people with diabetes and prediabetes. These levels were also linked to higher levels of HOMA-IR, BMI, FBS, HbA1C, and MDA, but lower levels of antioxidants. Furthermore, adjusting the above FFAs with age, sex, and antihypertensive medication increased T2DM development. SCFFA and ω3/6 fatty acids had a negative relationship with HOMA-IR, FBS, and insulin and a positive relationship with TAC. Adjusted SCFFA reduces T2DM risk. According to our models, total FFA is utilized to diagnose diabetes (AUC = 83.98, cut-off > 919 μM) and SCFFA for prediabetes (AUC = 82.32, cut-off < 39.56 μM). Total FFA (≥ 776 μM), LCFFA (≥ 613 μM), SFFA (≥ 471 μM), and USFFA (≥ 398 μM) all increase the risk of T2DM by increasing OS, BMI, and HOMA-IR. On the other hand, SCFFAs (≥ 38.7 μM) reduce the risk of T2DM by reducing BMI, HOMA-IR, and OS. SCFFAs and total FFAs can be used for the diagnosis of prediabetes and diabetes, respectively.
- Open Access
- 1 May 2023
- Published by Apex Publishing in Scientific Journal of Kurdistan University of Medical Sciences
- Vol. 28 (2) , 1-11
Evaluation of the effect of interleukin-1 receptor associated kinase (IRAK) inhibitor on PPAR.γ and GLUT.4 genes expression in muscle tissueof insulin resistant mice
Background and Aim: Diabetes mellitus is a metabolic disorder with an increasing prevalence in the world. Obesity plays a pivotal role in increasing the risk of diabetes, metabolic syndrome, hypertension and cardiovascular diseases. Obesity dependent mild-inflammation leads to an imbalance in the secretion of adipokines and thereby reduces insulin sensitivity. The TLR ...
- 1 May 2023
- Published by Apex Publishing in Scientific Journal of Kurdistan University of Medical Sciences
- Vol. 28 (2) , 1-11
Open AccessEvaluation of the effect of interleukin-1 receptor associated kinase (IRAK) inhibitor on PPAR.γ and GLUT.4 genes expression in muscle tissueof insulin resistant mice
Background and Aim: Diabetes mellitus is a metabolic disorder with an increasing prevalence in the world. Obesity plays a pivotal role in increasing the risk of diabetes, metabolic syndrome, hypertension and cardiovascular diseases. Obesity dependent mild-inflammation leads to an imbalance in the secretion of adipokines and thereby reduces insulin sensitivity. The TLR ...